Sarcoma Clinical Trial
Official title:
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors
Verified date | March 2, 2017 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purposes of this study are fourfold. It will 1) determine what dose of interleukin-12
(IL-12) and interleukin-2 (IL-2) combination therapy can be given safely to patients with
advanced cancer; 2) evaluate the side effects of this treatment; 3) examine how the body
handles this drug combination; and 4) determine whether and how the therapy may cause the
immune system to stop or slow tumor growth.
IL-2 is an approved drug for treating melanoma and kidney cancer. IL-12 is an experimental
drug that has shown anti-cancer activity in animals, shrinking tumors and slowing their
growth. Animal studies suggest that given together, the drugs may be more effective against
cancer than either one singly.
Patients 18 years of age and older with advanced solid-tumor cancers (kidney, breast, lung,
sarcomas and others) that do not improve with standard treatment may qualify for this study.
Candidates will have a physical examination, including blood and urine tests,
electrocardiogram (EKG) and echocardiogram, DTH skin test (to test the function of the immune
system), chest X-ray and lung function tests to determine eligibility. Bone marrow biopsy and
imaging procedures such as CT and MRI scans may also be required. Patients over 50 years old
will also undergo exercise stress testing.
Treatment will consist of four courses of IL-2 and IL-12. On days one and nine of each
course, patients will receive three doses (one every 8 hours) of IL-2 intravenously (through
a vein). On days two, four, six, 10, 12 and 14, they will receive IL-12 intravenously. This
will be followed by a recovery period from days 15 through 35. This regimen will be repeated
for another three cycles; patients who show benefit without severe side effects may continue
for additional cycles. Treatment for the first cycle will be administered in the hospital. If
the drugs are well tolerated, additional therapy may be given on an outpatient basis.
A biopsy (removal of a small sample of tumor tissue) will be done at the beginning of the
study, after completing the first treatment cycle, and possibly again when the cancer slows,
stops or gets worse, or if the patient leaves the study. These tumor samples will be examined
to evaluate the effects of treatment. Several blood samples also will be collected during the
course of treatment to monitor immune system effects. A device called a heparin lock may be
put in place to avoid multiple needle sticks.
...
Status | Terminated |
Enrollment | 39 |
Est. completion date | March 2, 2017 |
Est. primary completion date | October 6, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- INCLUSION CRITERIA: Adult patients 18 years of age and older. Pathologically or cytologically-proven diagnosis of non-hematologic malignancy, and the presence of radiographically or clinically evaluable disease. Patients with solid tumors including renal, breast, lung carcinomas, as well as sarcomas for whom a proven more effective therapy does not exist. Patients with renal cell cancer will have received sunitinib or sorefinib or refused this option. Patients must not have received myelosuppressive chemotherapy, hormonal therapy, radiotherapy or immunotherapy within four weeks of entry onto this protocol. Estimated life expectancy of at least 12 weeks. ECOG performance status of 0 or 1. Patients must be free of acute infection or other significant systemic illness. Negative serologic testing for hepatitis B will be required to limit confounding variables in the assessment of the potential hepatic toxicity of this combination. Negative serologic testing for human immunodeficiency virus (HIV) will be required given the uncertain impact of rhIL-12 and/or rhIL-2 administration on viral replication, and the potential alterations in immune responsiveness among patients concurrently infected with HIV. Adequate hepatic and renal function as evidence by: Transaminases less than 2.5 times the upper limit or normal; Total serum bilirubin less than 2.0 mg/dl; Serum Cr less than 2.0 mg/dl or calculated creatinine clearance of greater than 60 ml/min/1.73M(2). Adequate bone marrow function (without growth factor support) as evidence by: Absolute Neutrophil count (ANC) greater than 1500 cells/mm(3); Platelets greater than 100,000/mm(3). For women of childbearing potential, a negative urine pregnancy test within 14 days prior to initiation of study therapy is required. For patients of child-bearing potential, contraceptive precautions must be maintained during study participation. Normal pulmonary function (as documented by PFTs), and for patients over the age of 50, normal stress thallium testing. Normal pulmonary function testing will be defined as DLCO greater than 60% of predicted and FEVI greater than 70% of predicted. EXCLUSION CRITERIA: Critically-ill or medically unstable patients. History or a presence of brain metastases. History of coronary artery disease, angina or myocardial infarction. Presence of clinically significant pleural effusion. History of malignant hyperthermia are. Concurrent or history of autoimmune disease. History of congenital or acquired coagulation disorder. Patients with a history of ongoing or intermittent bowel obstruction. Women who are pregnant or lactating will be excluded. Systemic corticosteroids, radiotherapy, chemotherapy, or other investigational agents within 4 weeks prior to study entry. Patients who have received any of the following agents with known immunomodulatory effects within 4 weeks prior to study entry: G-CSF/GM-CSF, interferons or interleukins, growth hormone, IVIG, retinoic acid. Patients with a history of previous therapy with rhIL-12 will be excluded from study participation. For patients with renal cell carcinoma, a history of therapy with rhIL-2 will not exclude patients from study participation. Patients with concurrent administration of any other investigational agent. Patients with hematologic malignancies including leukemia or lymphoma. History of bone marrow or stem-cell transplantation. Intercurrent radiation therapy patients will be allowed on study if in the opinion of the principal investigator(s) its use is not necessitated by disease progression. For patients with disease progression, radiation therapy will be administered as clinically indicated and the patient will be withdrawn from study participation. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007-8. — View Citation
Rubin JT. Interleukin-2: its biology and clinical application in patients with cancer. Cancer Invest. 1993;11(4):460-72. Review. — View Citation
Ruscetti FW, Morgan DA, Gallo RC. Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol. 1977 Jul;119(1):131-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD and DLTof IL-12 in combination with IL-2 | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |